scispace - formally typeset
S

Serge Gauthier

Researcher at McGill University

Publications -  715
Citations -  61038

Serge Gauthier is an academic researcher from McGill University. The author has contributed to research in topics: Dementia & Disease. The author has an hindex of 93, co-authored 637 publications receiving 52775 citations. Previous affiliations of Serge Gauthier include Hamamatsu University School of Medicine & La Salle University.

Papers
More filters
Book

Vascular Cognitive Impairment in Clinical Practice

TL;DR: The use of the term “vascular cognitive impairment” (VCI) has a fairly recent history and was conceptualized in two widely promulgated sets of consensus-based criteria.
Journal ArticleDOI

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

TL;DR: A novel trial in the development of rivastigmine, as it uses a design that does not include a placebo arm, is recruiting patients with severe AD, and includes an ADL measure as a co-primary efficacy variable.
Journal ArticleDOI

In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals

TL;DR: Several novel positron emission tomography radiopharmaceuticals targeting tau tangles have been developed, allowing for non-invasive in vivo quantification of tau pathology and holding the promise of advancing the development of theoretical models and advancing the understanding of the natural history of AD and non-AD tauopathies.
Journal ArticleDOI

International price comparisons of Alzheimer's drugs: a way to close the affordability gap.

TL;DR: Alzheimer's drugs, albeit available, are often unaffordable for those who need them most, and in terms of PPP, Alzheimer's drugs in other low- and middle- income countries are much more expensive than in high-income countries.
Journal ArticleDOI

Severe Impairment Battery Language scale: A language-assessment tool for Alzheimer's disease patients

TL;DR: A new scale, based on the language subscale of the Severe Impairment Battery, is created as a sensitive and reliable measurement of treatment effects on language performance in Alzheimer's disease patients.